Dupilumab may worsen hair loss in patients with alopecia areata.
January 2026 in “Acta Dermato Venereologica” Dupilumab effectively treats severe skin issues in a rare genetic disorder.
November 2025 in “Вопросы современной педиатрии” Treating Netherton syndrome with growth hormone and dupilumab improves growth safely.
June 2025 in “Dermatopathology” Dupilumab and COVID-19 can worsen or trigger psoriasis.
IVIG and dupilumab effectively improved symptoms in a child with Netherton syndrome.
November 2024 in “Dermatology Online Journal” Dupilumab may help treat alopecia areata, but more research is needed.
September 2024 in “Вопросы современной педиатрии” Dupilumab helped an 11-year-old boy regrow hair and reduce skin rashes.
June 2024 in “British Journal of Dermatology” Dupilumab can both trigger and treat alopecia areata, often leading to hair regrowth.
June 2024 in “British Journal of Dermatology” Dupilumab can both cause and treat alopecia areata, with many patients experiencing hair regrowth.
August 2023 in “Clinical and experimental dermatology and therapies” Dupilumab may help hair regrowth in some patients with severe atopic dermatitis, but results vary.
COVID-19 can cause skin problems and affect dermatology treatments, with recommendations for skin care and cautious use of certain drugs.
Daily use of emollients from birth may reduce atopic dermatitis in infants, but results are mixed.
October 2022 in “Portuguese journal of dermatology and venereology” Dupilumab led to complete hair regrowth and improved skin condition in a young man with severe eczema and hair loss.
Dupilumab helped improve skin and prevent new lesions in a child with a rare immune disorder and severe eczema.
50 citations
,
March 2021 in “Journal of investigational allergology & clinical immunology” Dupilumab is being tested for many new skin, respiratory, and gastrointestinal conditions.
1 citations
,
April 2019 in “Journal of Investigative Dermatology” Dupilumab is effective and safe for treating moderate-to-severe atopic dermatitis in adolescents.
September 2023 in “Journal of the American Academy of Dermatology” 2 citations
,
October 2023 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Dupilumab significantly improved a 5-year-old girl's prurigo nodularis without side effects.
25 citations
,
May 2019 in “Biologics” Dupilumab can cause rare side effects like a rash on the face and neck.
July 2025 in “Ultrasound in Medicine & Biology”
2 citations
,
July 2023 in “Journal of cosmetic dermatology” JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.
20 citations
,
July 2024 in “Archives of Dermatological Research” Dupilumab helps children with alopecia areata regrow hair safely.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Adding dupilumab led to almost complete hair regrowth in a patient with alopecia areata who only partially responded to baricitinib.
February 2026 in “Indian Journal of Skin Allergy” Ruxolitinib cream effectively treats skin conditions like atopic dermatitis and vitiligo with minimal side effects.
2 citations
,
June 2022 in “Journal of cosmetic dermatology” Dupilumab can help hair regrowth but may also trigger alopecia areata.
July 2024 in “Journal of Investigative Dermatology”
1 citations
,
April 2016 in “Journal of The American Academy of Dermatology” Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.
29 citations
,
July 2019 in “Dermatologic Therapy” Dupilumab can both heal and cause hair loss.
October 2023 in “Frontiers in Medicine” Dupilumab helped a 4-year-old grow hair back after another treatment failed.
24 citations
,
July 2021 in “Pharmaceutics” Ruxolitinib cream effectively targets and treats inflammatory skin diseases.